111 related articles for article (PubMed ID: 38500226)
1. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of pharmacological treatments for Dravet syndrome: Systematic review and network meta-analysis.
Xia D; Zhang P; Chen Y; Liu X; Chen Y
Seizure; 2024 Apr; 117():90-97. PubMed ID: 38354598
[TBL] [Abstract][Full Text] [Related]
3. Dravet syndrome seizure frequency and clustering: Placebo-treated patients in clinical trials.
Nabbout R; Hyland K; Loftus R; Nortvedt C; Devinsky O
Epilepsy Behav; 2024 Jun; 155():109774. PubMed ID: 38643658
[TBL] [Abstract][Full Text] [Related]
4. Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials.
Devinsky O; Hyland K; Loftus R; Nortvedt C; Nabbout R
Epilepsy Behav; 2024 Jul; 156():109805. PubMed ID: 38677101
[TBL] [Abstract][Full Text] [Related]
5. Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity.
Beers JL; Zhou Z; Jackson KD
Drug Metab Dispos; 2024 May; 52(6):508-515. PubMed ID: 38286636
[TBL] [Abstract][Full Text] [Related]
6. Potential Clinical Benefits of CBD-Rich
Pamplona FA; da Silva LR; Coan AC
Front Neurol; 2018; 9():759. PubMed ID: 30258398
[TBL] [Abstract][Full Text] [Related]
7. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.
Rosenberg EC; Louik J; Conway E; Devinsky O; Friedman D
Epilepsia; 2017 Aug; 58(8):e96-e100. PubMed ID: 28617940
[TBL] [Abstract][Full Text] [Related]
8. Enhanced brain-targeting and efficacy of cannabidiol via RVG-Exo/CBD nanodelivery system.
Li Y; Chen Z; Guo J; Meng D; Pang X; Sun Z; Pu L; Yang S; Yang M; Peng Y
Biochem Biophys Res Commun; 2024 Sep; 725():150260. PubMed ID: 38878760
[TBL] [Abstract][Full Text] [Related]
9. Transdermal Delivery of Cannabidiol for the Management of Acute Inflammatory Pain: A Comprehensive Review of the Literature.
Lefebvre È; Tawil N; Yahia L
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892047
[TBL] [Abstract][Full Text] [Related]
10. Effects of Cannabidiol in Adolescent and Young Adult Depressive and Anxiety Disorders: A Systematic Review of Clinical and Preclinical Research.
Denson RK; Brooks J; Pinna G; Crane NA
Adolesc Psychiatry (Hilversum); 2023; 13(3):176-194. PubMed ID: 38919887
[TBL] [Abstract][Full Text] [Related]
11. Exploring the safety of cannabidiol (CBD): A comprehensive in vitro evaluation of the genotoxic and mutagenic potential of a CBD isolate and extract from Cannabis sativa L.
Štern A; Novak M; Kološa K; Trontelj J; Žabkar S; Šentjurc T; Filipič M; Žegura B
Biomed Pharmacother; 2024 Jun; 177():116969. PubMed ID: 38908200
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and liver toxicity of cannabidiol.
Chen S; Li Y; Li X; Wu Q; Puig M; Moulin F; Gingrich J; Guo L
J Environ Sci Health C Toxicol Carcinog; 2024 Jun; ():1-17. PubMed ID: 38904421
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Potential of CBD for Health Benefits: an Overview.
Santos I; P P Oliveira MB; Casas A; Fidalgo J; Almeida H
Curr Drug Discov Technol; 2024 Jun; ():. PubMed ID: 38847170
[TBL] [Abstract][Full Text] [Related]
14. Assessing a potential therapeutic effect of cannabidiol for lower back pain, requires appropriately designed studies.
Finsterer J
Ann Agric Environ Med; 2024 Jun; 31(2):159. PubMed ID: 38940097
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.
Aderinto N; Olatunji G; Kokori E; Ajayi YI; Akinmoju O; Ayedun AS; Ayoola OI; Aderinto NO
Eur J Med Res; 2024 Mar; 29(1):182. PubMed ID: 38500226
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
17. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
19. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
